How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, gender, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about rucaparib

Marketing authorisation indication

Rucaparib (Rubraca, Clovis Oncology) is indicated as 'monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.'

Dosage in the marketing authorisation

Rucaparib is taken orally as tablets. The recommended dosage is 600 mg (two 300 mg tablets) twice daily, with or without food (1,200 mg total daily dose).

Interruption of treatment or dose reduction can be considered for adverse event management (600 mg to 500 mg [two 250 mg tablets] to 400 mg [two 200 mg tablets] to 300 mg [one 300 mg tablet]).

Patients should start maintenance treatment no later than 8 weeks after completion of their final dose of the platinum-containing regimen.

Price

The list price for rucaparib taken from the company submission is £3,562.00 per 60‑tablet pack of 300 mg, 250 mg or 200 mg tablets.

The company estimates that the average cost of a course of treatment until discontinuation is £110,897 (estimated from the deterministic base-case economic analysis using the list price).

The company has a commercial arrangement, which would have applied if the technology had been recommended.